AstraZeneca Loses Challenge To Medicare Drug Price Program

AstraZeneca Loses Challenge To Medicare Drug Price Program
FILE PHOTO: FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo/File Photo

A Delaware federal judge has dealt a significant blow to AstraZeneca, rejecting the pharmaceutical giant’s challenge to the Medicare price negotiation program. The decision, delivered by U.S. District Chief Judge Colm Connolly, aligns with a crucial stance of the Biden administration, affirming the program’s voluntary nature.

Enter Email to View Articles


AstraZeneca Loses Challenge To Medicare Drug Price Program : Defeat in the Courtroom

In a compelling 47-page opinion, Judge Connolly sided with the federal government, granting an early victory and dismantling AstraZeneca’s legal arguments. The ruling underscored the absence of standing for the drugmaker on two pivotal claims. Crucially, the court highlighted that AstraZeneca cannot be compelled to engage in price negotiations with the Centers for Medicare & Medicaid Services (CMS).

Voluntary, Not Involuntary

The crux of the ruling rested on the determination that AstraZeneca’s participation in Medicare remains voluntary. Judge Connolly emphasized that without coercion, the company lacks a protected property interest in dictating prices to the government. This strategic maneuver effectively undermined AstraZeneca’s attempts to challenge the program’s legality.

AstraZeneca Loses Challenge To Medicare Drug Price Program : Dismissing Claims

Judge Connolly swiftly dismissed two claims brought forth under the Administrative Procedure Act, citing AstraZeneca’s failure to demonstrate a tangible injury-in-fact resulting from CMS guidance. The absence of a compelling argument on this front rendered the company devoid of standing, sealing its legal fate.

AstraZeneca Loses Challenge To Medicare Drug Price Program : The Farxiga Factor

Central to the case was CMS’s inclusion of AstraZeneca’s Farxiga in a groundbreaking price negotiation initiative aimed at reducing costs for seniors. Farxiga, a versatile drug used in treating diabetes, heart disease, and chronic kidney disease, assumed a pivotal role in the legal tussle, underscoring the stakes involved.

Legal Landscape

The case, titled AstraZeneca Pharmaceuticals LP v. Becerra et al., unfolded in the U.S. District Court for the District of Delaware, marked by legal skirmishes and high-stakes maneuvers. Despite AstraZeneca’s vigorous legal challenge, the court’s resounding verdict has firmly upheld the Medicare drug price program, signaling a significant setback for the pharmaceutical heavyweight.